Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

BACKGROUND: Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Beelen, Karin, Opdam, Mark, Severson, Tesa, Koornstra, Rutger, Vincent, Andrew, Wesseling, Jelle, Sanders, Joyce, Vermorken, Jan, van Diest, Paul, Linn, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057037/
https://www.ncbi.nlm.nih.gov/pubmed/30041599
http://dx.doi.org/10.1186/s12885-018-4516-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057037/
https://www.ncbi.nlm.nih.gov/pubmed/30041599
http://dx.doi.org/10.1186/s12885-018-4516-1

Ejemplares similares